Trials / Active Not Recruiting
Active Not RecruitingNCT07155759
Long-term Outcomes of Prostate Cancer Screening
Long-term Outcomes of Prostate Cancer Screening Using PSA, Biomarkers and MRI: The STHLM3MRI Trial
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 7,500 (estimated)
- Sponsor
- Karolinska Institutet · Academic / Other
- Sex
- Male
- Age
- 50 Years – 74 Years
- Healthy volunteers
- Accepted
Summary
This study is an expansion of the screening-by-invitation STHLM3MRI trial for detection of prostate cancer. In summary, we assess longterm outcomes (prostate cancer mortality, incidence and resource use) in men (i) invited and randomized to a screening program using PSA, a biomarker test and MRI; (ii) invited and randomized to a single PSA test with prostate biopsies followed by opportunistic testing and (iii) population controls. Mortality is verified through register data, disease verification is made through in-study biopsy results and registry data.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | PSA/Stockholm3/MRI | Stockholm3+PSA followed by MRI of the prostate |
| DIAGNOSTIC_TEST | PSA | PSA followed by standard biopsies |
Timeline
- Start date
- 2024-11-01
- Primary completion
- 2025-10-01
- Completion
- 2035-11-01
- First posted
- 2025-09-04
- Last updated
- 2025-09-04
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT07155759. Inclusion in this directory is not an endorsement.